Ranolazine block of human NaV1.4 sodium channels and paramyotonia congenita mutants

Channels

Volumn 5, Issue 2, 2011, Pages

  El Bizri, Nesrine ^a   Kahlig, Kristopher M ^a   Shryock, John C ^a   George Jr , Alfred L ^b   Belardinelli, Luiz ^a   Rajamani, Sridharan ^a  

^a GILEAD SCIENCES   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Action potential; Angina; Excitability; Markov model; Na channels; Paramyotonia congenita; SCN4A; Skeletal muscle

Indexed keywords

RANOLAZINE; SODIUM CHANNEL NAV1.4;

ARTICLE; CELL STRAIN HEK293; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG POTENCY; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; HYPERPOLARIZATION; IC 50; MUSCLE ACTION POTENTIAL; MUSCLE FIBER MEMBRANE STEADY POTENTIAL; MUSCLE INJURY; PROTEIN EXPRESSION; SKELETAL MUSCLE; SODIUM CURRENT; THOMSEN DISEASE; WHOLE CELL;

ANGINA;

EID: 79952570607     PISSN: 19336950     EISSN: 19336969     Source Type: Journal    
DOI: 10.4161/chan.5.2.14851     Document Type: Article

References (47)

1. Ptacek LJ, George AL Jr, Barchi RL, Griggs RC, Riggs JE, Robertson M, et al. Mutations in an S4 segment of the adult skeletal muscle sodium channel cause paramyotonia congenita. Neuron 1992; 8:891-7.
2. + channel alpha-subunit in hyperkalaemic periodic paralysis. Nature 1991; 354:387-9.
3. Lerche H, Heine R, Pika U, George AL Jr, Mitrovic N, Browatzki M, et al. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. J Physiol 1993; 470:13-22. (Pubitemid 23322474)
4. George AL Jr. Inherited disorders of voltage-gated sodium channels. J Clin Invest 2005; 115:1990-9.
5. Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci 2006; 29:387-415. (Pubitemid 44476851)
6. Matthews E, Fialho D, Tan SV, Venance SL, Cannon SC, Sternberg D, et al. The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain 2010; 133:9-22.
7. Chahine M, George AL Jr, Zhou M, Ji S, Sun W, Barchi RL, et al. Sodium channel mutations in paramyotonia congenita uncouple inactivation from activation. Neuron 1994; 12:281-94. (Pubitemid 24071294)
8. Yang N, Ji S, Zhou M, Ptacek LJ, Barchi RL, Horn R, et al. Sodium channel mutations in paramyotonia congenita exhibit similar biophysical phenotypes in vitro. Proc Natl Acad Sci USA 1994; 91:12785-9.
9. Groome JR, Fujimoto E, George AL, Ruben PC. Differential effects of homologous S4 mutations in human skeletal muscle sodium channels on deactivation gating from open and inactivated states. J Physiol 1999; 516:687-98. (Pubitemid 29201895)
10. Lehmann-Horn F, Rudel R, Ricker K. Membrane defects in paramyotonia congenita (Eulenburg). Muscle Nerve 1987; 10:633-41. (Pubitemid 17130876)
11. Lehmann-Horn F, Rudel R. Hereditary nondystrophic myotonias and periodic paralyses. Curr Opin Neurol 1995; 8:402-10.
12. Lehmann-Horn F, Rudel R, Ricker K, Lorkovic H, Dengler R, Hopf HC. Two cases of adynamia episodica hereditaria: in vitro investigation of muscle cell membrane and contraction parameters. Muscle Nerve 1983; 6:113-21. (Pubitemid 13092080)
13. Cannon SC. Spectrum of sodium channel disturbances in the nondystrophic myotonias and periodic paralyses. Kidney Int 2000; 57:772-9. (Pubitemid 30434765)
14. + channel mutation in adult human skeletal muscle. Ann Neurol 1996; 39:599-608.
15. th Ed. Philadelphia, PA: Lippincott, Williams & Wilkins 2008; 1493.
16. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110:904-10. (Pubitemid 39136212)
17. Fredj S, Sampson KJ, Liu H, Kass RS. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br J Pharmacol 2006; 148:16-24. (Pubitemid 43675596)
18. V 1.1 mutations. Br J Pharmacol 2010; 161:1414-26.
19. + current by ranolazine. Heart Rhythm 2009; 6:1625-31.
20. + channels by ranolazine. Channels (Austin) 2008; 2:449-60.
21. + channel isoforms by ranolazine. Mol Pharmacol 2008; 73:940-8.
22. + current in paramyotonia congenita muscle. Brain 1999; 122:1085-92.
23. - conductance in resealed muscle fibre segments from patients with myotonic dystrophy. J Physiol 1990; 425:391-405.
24. Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation 2006; 113:2462-72. (Pubitemid 43948054)
25. Jurkat-Rott K, Holzherr B, Fauler M, Lehmann-Horn F. Sodium channelopathies of skeletal muscle result from gain or loss of function. Pflugers Arch 2010; 460:239-48.
26. Desaphy JF, De Luca A, Didonna MP, George AL Jr, Camerino Conte D. Different flecainide sensitivity of hNaV1.4 channels and myotonic mutants explained by state-dependent block. J Physiol 2004; 554:321-34. (Pubitemid 38181347)
27. Desaphy JF, De Luca A, Tortorella P, De Vito D, George AL Jr, Conte Camerino D. Gating of myotonic Na channel mutants defines the response to mexiletine and a potent derivative. Neurology 2001; 57:1849-57. (Pubitemid 33096694)
28. + channels expressed in a mammalian cell line. J Physiol 1996; 496:275-86.
29. Weckbecker K, Wurz A, Mohammadi B, Mansuroglu T, George AL Jr, Lerche H, et al. Different effects of mexiletine on two mutant sodium channels causing paramyotonia congenita and hyperkalemic periodic paralysis. Neuromuscul Disord 2000; 10:31-9. (Pubitemid 30006861)
30. Cannon SC, Brown RH Jr, Corey DP. Theoretical reconstruction of myotonia and paralysis caused by incomplete inactivation of sodium channels. Biophys J 1993; 65:270-88. (Pubitemid 23206060)
31. Kahlig KM, Misra SN, George AL Jr. Impaired inactivation gate stabilization predicts increased persistent current for an epilepsy-associated SCN1A mutation. J Neurosci 2006; 26:10958-66. (Pubitemid 44772186)
32. Mohammadi B, Jurkat-Rott K, Alekov A, Dengler R, Bufler J, Lehmann-Horn F. Preferred mexiletine block of human sodium channels with IVS4 mutations and its pH-dependence. Pharmacogenet Genomics 2005; 15:235-44. (Pubitemid 40569895)
33. Rosenfeld J, Sloan-Brown K, George AL Jr. A novel muscle sodium channel mutation causes painful congenital myotonia. Ann Neurol 1997; 42:811-4. (Pubitemid 27481556)
34. Chew CY, Collett J, Singh BN. Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias. Drugs 1979; 17:161-81. (Pubitemid 9120292)
35. Desaphy JF, Camerino DC, Tortorella V, De Luca A. Effect of mexiletine on sea anemone toxin-induced non-inactivating sodium channels of rat skeletal muscle: a model of sodium channel myotonia. Neuromuscul Disord 1999; 9:182-9. (Pubitemid 29336034)
36. Roden DM. Antiarrhythmic drugs. In: Hardman JG, Ed. Goodman and Gilman's The Pharmacological Basics of Therapeutics. New York: McGraw-Hill 1996; 839-74.
37. Aoike F, Takahashi MP, Sakoda S. Class Ic antiarrhythmics block human skeletal muscle Na channel during myotonia-like stimulation. Eur J Pharmacol 2006; 532:24-31.
38. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. Jama 2007; 297:1775-83. (Pubitemid 46658646)
39. Nash DT, Nash SD. Ranolazine for chronic stable angina. Lancet 2008; 372:1335-41.
40. George AL Jr, Komisarof J, Kallen RG, Barchi RL. Primary structure of the adult human skeletal muscle voltage-dependent sodium channel. Ann Neurol 1992; 31:131-7.
41. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ. Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981; 391:85-100. (Pubitemid 11012976)
42. Carr DB, Day M, Cantrell AR, Held J, Scheuer T, Catterall WA, et al. Transmitter modulation of slow, activity-dependent alterations in sodium channel availability endows neurons with a novel form of cellular plasticity. Neuron 2003; 39:793-806. (Pubitemid 37088091)
43. Vilin YY, Ruben PC. Slow inactivation in voltage-gated sodium channels: molecular substrates and contributions to channelopathies. Cell Biochem Biophys 2001; 35:171-90. (Pubitemid 33622686)
44. Hines ML, Carnevale NT. NEURON: a tool for neuroscientists. Neuroscientist 2001; 7:123-35. (Pubitemid 32245018)
45. Clancy CE, Zhu ZI, Rudy Y. Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol 2007; 292:66-75.
46. Starmer CF, Nesterenko VV, Undrovinas AI, Grant AO, Rosenshtraukh LV. Lidocaine blockade of continuously and transiently accessible sites in cardiac sodium channels. J Mol Cell Cardiol 1991; 23:73-83.
47. + channels. Anesthesiology 2010; 113:160-74.